Derisk you biotech assets with 3 key coniderations.

Learn from drug development expert Angelique Greco and medtech-biotech founders and investors with tangible examples that show how real de-risking plays out.

🔍 What You’ll Learn

Drug discovery feels like a maze when you're early in your career, especially when you're trying to build a biotech path without wasting years or cash. This episode gives you a clear way to turn solid science into something fundable.

You’ll learn:

• Where to find real support, from incubators to honest VC advice

• Why early commercial input matters and how to fix your market slide

• How smart entry points like animal health or adjacent indications de-risk your program and boost your funding chances

Action: Press play if you want 20 minutes that cut months of guesswork.

🧠 About the Guest

This episode brings insights from ShanShan Wang (RoamTech AI), Anushi Rajapaksa (Misti), Maryam Parviz (SDIP Innovations), Mike Lamprecht (Tenmile), and Ben Wright (Mimetic MedTech Foundry) on how founders can derisk and resource their team.

Plus why you do not always need an indication at the start, with lessons from Dr Chris Burns, whose team discovered Momelotinib in Australia before its FDA approval.

📌 Episode Highlights

00:00 Why de-risking matters for early biotech founders

00:20 Two angles: advice and smarter indication choices

01:00 How drug discovery fits a STEM entrepreneur path

01:40 Upskilling vs burning cash and time

02:10 Three pillars: compass, investors, venture studios

Roadmap & Upskilling

03:00 The value of a commercialization roadmap

03:45 Han Wang on first seeing the map

04:30 Anushi Rajapaksa on IP, regulatory and evolving the plan

06:00 Where to find training, Bridge program, NSW program

07:00 Why programs matter for network and support

08:00 Maryam Parviz on global doors opening

09:30 What you cannot Google: real conversations

10:30 How informal mentoring happens

11:00 Using tech transfer offices even if you're external

Investor Advice

12:00 Why VC advice matters before fundraising

13:00 Mike Lamprecht on critical early experiments

14:00 What a realistic market conversation looks like

Bridging Your Gaps

15:00 When to stop upskilling and bring experts

15:40 Ben Wright on scaling support instead of solo learning

16:00 How investors view founders who learn on the job

17:00 How venture studios derisk early biotech and medtech

18:00 Why structure and clinical champions matter

Success Exists

18:45 Momelotinib as a real success story

19:10 When starting with the molecule works

20:00 Dr Chris Burns: from discovery to 2023 approval

Smarter Entry Points

22:00 Why some programs need a side door

22:30 What to check before picking an entry point

23:00 Ivermectin from livestock to humans

24:30 Ketamine and S-ketamine into severe depression

26:00 How new IP opened new paths

26:40 The semaglutide pivot

Final Takeaways

27:00 Do not do it alone

27:15 Get advice early, including from VC

27:30 Philanthropy can be a real path

27:45 Be realistic and optimistic, success exists

Want to craft a career story that opens doors?

I help STEMM professionals speak with clarity, confidence, and purpose and show up as thought leaders —so the right opportunities find you.

📬 Let’s connect: angeliquegreco.com.au | LinkedIn

⭐️ Help More People Reinvent Their Careers

If you enjoyed this episode, please:

• ✅ Leave a quick ⭐️⭐️⭐️⭐️⭐️ review on Apple Podcasts or Spotify 🙏
• ♻️ Share it with a friend who's questioning their path in STEM

Hosted on Acast. See acast.com/privacy for more information.